Immuneering Corp
About Immuneering Corp
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2023
- $0
- Net income
- -$56.0M
- Total assets
- $232.0M
- Market cap
- $276.3M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $59.4M
- Operating income
- -$59.4M
- Income tax
- $0
- Net income
- -$56.0M
- EPS (basic)
- $-1.27
- EPS (diluted)
- $-1.27
Balance sheet
- Total assets
- $232.0M
- Current assets
- $176.2M
- Total liabilities
- $13.5M
- Current liabilities
- $10.1M
- Shareholders’ equity
- $218.5M
Cash flow
- Operating cash flow
- -$45.3M
- Investing cash flow
- -$88.7M
- Financing cash flow
- $226.6M
- Net cash flow
- $92.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $276.3M
- EPS (diluted)
- $-1.27
- Shares outstanding
- 70.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 30, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $56.0M in FY2023.
- Trading 58% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Immuneering Corp.
Write a review
News about Immuneering Corp
News & sentiment via Polygon.io
